Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease (AD) places a significant burden on health care systems worldwide. As new treatments are developed, their cost-effectiveness is often assessed to help health care professionals make informed decisions. In addition to the more common practice of assessing direct medical costs, indirect costs, including time spent in caregiving, should be evaluated. METHODS: This study examined the potential effects of the dual cholinesterase inhibitor rivastigmine (Exelon) on caregivers of patients with AD. Results from two 26-week, placebo-controlled trials have demonstrated the clinically relevant and statistically significant efficacy of rivastigmine (6-12 mg/day) compared to placebo, on cognition, activities of daily living, and global functioning. By delaying progression of AD, significant savings in caregiver burden are anticipated, as measured by time spent caregiving and its related costs. Data collected in a prospective, observational study of AD patients and their caregivers were used to establish the relationship between disease severity (based on Mini-Mental State Examination [MMSE] score) and time spent caregiving (according to the 5-item Caregivers Activity Survey score). A significant correlation was observed between the two scores (N = 43, r = -.56, p < .0001), demonstrating that more time for supervision from caregivers is required as the disease progresses. This finding was used to estimate the reduced caregiver burden resulting from the delay in disease progression that was demonstrated with use of rivastigmine. RESULTS: Over a 2-year period, the reduction in time spent in caregiving reached 691 hours for caregivers of patients with mild AD (MMSE score 21-30), resulting in a total savings of approximately 11,253 dollars. Treatment of patients with moderately severe AD was also evaluated. The trend was similar but the impact was less, suggesting an economic benefit to early therapy. CONCLUSION: Early diagnosis and a pharmacologic intervention that allows the patients to remain at home longer by delaying disease progression would have a beneficial impact on patients, caregivers, and payers, and should therefore be encouraged through initiatives designed to identify and treat patients early in the course of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Cited by
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
An estimate of the total worldwide societal costs of dementia in 2005
Wimo, A., Winblad, B., & Jönsson, L. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.02.001 · Cited by 300
Rivastigmine for Alzheimer's disease
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub2 · Cited by 296
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57
Biernetzky, O. A., Thyrian, J. R., Boekholt, M., Berndt, M., Hoffmann, W., Teipel, S. J., & Kilimann, I. (2025) · JMIR Aging · doi:10.2196/59942 · Cited by 4
Metadata
- Authors
- Marin, D., Amaya, K., Casciano, R., Puder, K. L., Casciano, J., Cuccia, A. J., Chang, S., Snyder, E. H., & Cheng, I.
- Venue
- International Psychogeriatrics
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 15
- Issue
- 4
- Pages
- 385-398
- ISSN
- 1041-6102 (ISSN-L)
- OpenAlex
- W2135897934
- Cited by
- 43
- References
- 3
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer’s Disease. https://app.cochat.ai/papers/10.1017/s1041610203009633
- The paper
- Marin, D., Amaya, K., Casciano, R., Puder, K. L., Casciano, J., Cuccia, A. J., Chang, S., Snyder, E. H., & Cheng, I. (2003). Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer’s Disease. International Psychogeriatrics. https://doi.org/10.1017/s1041610203009633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.